Kyverna Therapeutics, Inc. KYTX Increase Decrease In Other Accrued Expenses And Current Liabilities
Increase Decrease In Other Accrued Expenses And Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept kytx:IncreaseDecreaseInOtherAccruedExpensesAndCurrentLiabilities.
The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kyverna Therapeutics, Inc.'s increase decrease in other accrued expenses and current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kyverna Therapeutics, Inc.'s increase decrease in other accrued expenses and current liabilities?
- Kyverna Therapeutics, Inc. (KYTX) reported increase decrease in other accrued expenses and current liabilities of -$4.35M in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s increase decrease in other accrued expenses and current liabilities changed year-over-year?
- Kyverna Therapeutics, Inc.'s increase decrease in other accrued expenses and current liabilities decreased by 88.7% year-over-year, from -$2.31M to -$4.35M.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s increase decrease in other accrued expenses and current liabilities?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s increase decrease in other accrued expenses and current liabilities has grown at a -45.2% compound annual growth rate (CAGR), from $2.66M to -$800K.
- What does increase decrease in other accrued expenses and current liabilities mean?
- This represents the net change in miscellaneous short-term liabilities that have been incurred but not yet paid in cash. Fluctuations in this account reflect changes in the timing of payments for various operational obligations. A significant increase may indicate a temporary source of cash, while a decrease represents a cash outflow to settle these liabilities.